PDCD1 and hepatocellular carcinoma: Compared with anti-VEGFR-2 therapy alone, dual anti-PD-1/VEGFR-2 therapy can promote CD4+ T cell-induced vascular normalization, indicated by the increased density of microvessels covered by pericytes and the protection against increased hypoxia in HCC (197).